Point of Care Diagnostics/Testing Market Report Scope & Overview:

The Point of Care Diagnostics/Testing Market was valued at USD 50.35 Billion in 2025 and is expected to reach USD 93.63 Billion by 2035, growing at a CAGR of 6.40% from 2026-2035.

Point of care testing moves diagnosis out of the centralized lab and to the patient's bedside, a clinic counter, or a kitchen table, delivering results in minutes rather than the day or two a sample might otherwise spend in transit and processing. That shift matters most in infectious disease management, where a rapid positive or negative reading changes what a clinician does in the same visit rather than a follow-up call days later. Portable analyzers have also gotten genuinely good, not just smaller, closing much of the accuracy gap that used to be the trade-off for speed and pushing adoption well past emergency and rural settings into routine primary care.

Roche received FDA 510(k) clearance and a CLIA waiver in December 2025 for its first molecular point-of-care assay designed to identify Bordetella infections, including whooping cough, delivering results on the cobas Liat system in roughly 15 minutes. The clearance builds directly on Roche's June 2024 acquisition of LumiraDx's U.S. point-of-care technology business, a deal aimed squarely at strengthening decentralized testing capability rather than treating molecular point-of-care as a side project alongside the company's central lab franchise. Together the two moves show how deliberately the largest diagnostics makers are now building out near-patient molecular platforms as a core growth line.

Point of Care Diagnostics/Testing Market Trends

• Multiplex testing platforms capable of screening for several pathogens from a single sample continue gaining share over single-target rapid tests, particularly in respiratory and sexually transmitted infection panels.

• AI-assisted result interpretation is moving from pilot programs into commercial handheld devices, reducing operator-dependent reading errors on lateral flow and imaging-based tests.

• Home-based and self-testing adoption continues expanding beyond glucose and pregnancy tests into infectious disease and cardiometabolic monitoring, supported by growing consumer comfort with at-home results.

• Connectivity features linking point-of-care devices directly to electronic health records are becoming a standard purchasing requirement rather than a premium add-on for hospital and clinic buyers.

• Molecular point-of-care platforms using isothermal and rapid PCR chemistry continue narrowing the turnaround-time gap with lateral flow tests while retaining laboratory-grade sensitivity.

U.S. Point of Care Diagnostics/Testing Market Outlook

The U.S. Point of Care Diagnostics/Testing Market was valued at approximately USD 15.90 Billion in 2025 and is expected to reach approximately USD 27.85 Billion by 2035, growing at a CAGR of approximately 5.75%.

U.S. demand is anchored by a large hospital and urgent care network that has steadily shifted routine infectious disease and cardiometabolic testing away from central labs to cut turnaround time in emergency departments and outpatient clinics alike. An aging population managing multiple chronic conditions simultaneously has pushed demand for testing that fits into a single office visit rather than requiring a separate lab appointment, while growing retail clinic and pharmacy-based testing continues to pull volume further away from traditional hospital settings.

Abbott received FDA approval in June 2024 for over-the-counter versions of two continuous glucose monitoring systems, Lingo and Libre Rio, extending its established Libre sensor technology from a prescription-only clinical tool into a consumer wellness product available directly off pharmacy shelves. The move followed the FDA's Special 510(k) clearance the same month for bioMérieux's BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini, a compact multiplex system built for smaller clinics and urgent care sites that lack space for full laboratory-scale molecular platforms. Both clearances landed within weeks of each other, underscoring how quickly the FDA pipeline for near-patient testing has been moving.

Point of Care Diagnostics/Testing Market Segment Analysis

• By Product, the Infectious Disease Testing segment dominated the Point of Care Diagnostics/Testing Market with approximately 30.50% share in 2025, while the Tumor/Cancer Marker Testing segment is the fastest growing with a CAGR of approximately 9.80%.

• By Technology/Platform, the Lateral Flow Assays segment dominated the Point of Care Diagnostics/Testing Market with approximately 41.00% share in 2025, while the Molecular Diagnostics segment is the fastest growing with a CAGR of approximately 10.20%.

• By Sample Type, the Blood segment dominated the Point of Care Diagnostics/Testing Market with approximately 77.05% share in 2025, while the Saliva/Oral Fluid segment is the fastest growing with a CAGR of approximately 9.40%.

• By End User, the Hospitals segment dominated the Point of Care Diagnostics/Testing Market with approximately 38.60% share in 2025, while the Homecare/Self-Testing segment is the fastest growing with a CAGR of approximately 10.80%.

• By Mode of Purchase, the Prescription-Based segment dominated the Point of Care Diagnostics/Testing Market with approximately 68.40% share in 2025, while the Over-the-Counter segment is the fastest growing with a CAGR of approximately 9.60%.

By Product, infectious disease testing dominates, tumor/cancer marker testing grows fastest

Infectious disease testing dominated the product segment in 2025, holding approximately 30.50% share, because rapid detection genuinely changes clinical decisions within the same patient visit, whether that means starting antibiotics, isolating a patient, or ruling out a serious illness before it worsens. The category spans respiratory viruses, sexually transmitted infections, and emerging outbreak pathogens, giving it the broadest and most consistently ordered testing footprint across hospitals, clinics, and retail pharmacy settings alike. Continued global circulation of seasonal and emerging respiratory pathogens keeps ordering volume high year over year, reinforcing this segment's lead over every other product category by a wide margin.

Tumor and cancer marker testing is the fastest-growing product segment, expanding at a CAGR of approximately 9.80% over the forecast period, as point-of-care platforms increasingly bring biomarker screening that once required a central lab into oncology clinics and even primary care settings. Earlier detection windows and growing physician comfort with near-patient cancer marker results, rather than waiting days for a reference lab, continue pushing adoption. Manufacturers are also expanding assay menus to cover a wider range of tumor markers, giving clinicians more reason to order point-of-care panels instead of routing samples to central pathology labs.

By Technology/Platform, lateral flow assays dominates, molecular diagnostics grows fastest

Lateral flow assays held the largest platform share in 2025 at approximately 41.00%, given their simplicity, low cost, and genuinely rapid turnaround, qualities that make them the default choice wherever a test needs to work reliably outside a controlled lab environment. Their proven track record across pregnancy, infectious disease, and drugs-of-abuse testing keeps manufacturers investing in incremental sensitivity improvements rather than replacing the underlying format outright. Wide manufacturing scale built up over decades also keeps unit costs low enough to support high-volume screening programs across both developed and resource-limited healthcare settings worldwide.

Molecular diagnostics is the fastest-growing platform segment, expanding at a CAGR of approximately 10.20% over the forecast period, as isothermal and rapid PCR chemistry increasingly deliver laboratory-grade sensitivity in a near-patient format once exclusive to lateral flow's speed advantage. Hospitals and clinics are willing to pay a premium for that combination, particularly for respiratory and sexually transmitted infection panels where a false negative carries real clinical consequences. Continued miniaturization of PCR instrumentation is also opening molecular testing to smaller clinics and urgent care sites that previously lacked the space or budget for full laboratory-scale equipment.

By Sample Type, blood dominates, saliva/oral fluid grows fastest

Blood samples accounted for the large majority of point-of-care testing volume in 2025, at approximately 77.05% share, reflecting how many of the highest-volume test categories, including glucose, coagulation, and cardiometabolic panels, rely on a blood draw or fingerstick as the most clinically validated and widely trusted sample source available to near-patient testing. Decades of assay development built specifically around blood chemistry give this sample type an entrenched technical and regulatory advantage that newer sample formats have yet to fully match, particularly for tests requiring precise quantitative results rather than a simple positive or negative reading.

Saliva and oral fluid sample types are the fastest-growing sample category, expanding at a CAGR of approximately 9.40% over the forecast period, as manufacturers develop assays that trade a small amount of sensitivity for a meaningfully less invasive collection process. This trade-off proves particularly appealing for pediatric, home-based, and repeat-testing use cases where a fingerstick or venous draw creates genuine friction for the patient. Growing regulatory acceptance of saliva-based infectious disease and hormone testing continues widening the range of conditions this sample type can credibly address.

By End User, hospitals dominates, homecare/self-testing grows fastest

Hospitals remained the largest end-user setting in 2025, holding approximately 38.60% share, since emergency departments and inpatient wards depend on point-of-care testing to make rapid triage and treatment decisions where waiting for a central lab result simply isn't compatible with acute care timelines. Expanding outpatient and same-day surgical volumes within hospital systems continue reinforcing this dominant position, as does growing hospital investment in connected device fleets that feed results directly into electronic health records rather than requiring manual transcription at the bedside.

Homecare and self-testing is the fastest-growing end-user segment, expanding at a CAGR of approximately 10.80% over the forecast period, as consumer comfort with at-home results, built up substantially during the pandemic years, carries over into chronic disease monitoring and infectious disease screening well beyond glucose and pregnancy tests. Manufacturers are responding with simpler, app-connected formats designed specifically for non-clinical users, and retail pharmacy chains continue expanding shelf space dedicated to self-test kits rather than treating the category as a temporary pandemic-era offering.

By Mode of Purchase, prescription-based dominates, over-the-counter grows fastest

Prescription-based testing held the larger share in 2025 at approximately 68.40%, reflecting the continued dominance of hospital, clinic, and physician office settings where a clinician orders and interprets the test as part of a broader care encounter rather than a consumer purchasing a kit independently. Complex panels and tests tied to formal diagnosis or treatment decisions remain concentrated in this channel, since insurance reimbursement and clinical documentation requirements generally favor physician-ordered testing over self-directed purchases.

Over-the-counter testing is the fastest-growing purchase channel, expanding at a CAGR of approximately 9.60% over the forecast period, as regulatory pathways for consumer-facing rapid tests have genuinely opened up in recent years and retailers have kept infectious disease and other self-test categories stocked and visible on pharmacy shelves. Growing consumer willingness to pay out of pocket for convenient, immediate results, combined with manufacturers actively pursuing OTC clearance for products once sold prescription-only, continues pushing this channel's growth well above the broader mode-of-purchase category average.

Regional Analysis

North America Point of Care Diagnostics/Testing Market Insights

North America dominated the Point of Care Diagnostics/Testing Market in 2025 with approximately 37.10% market share, anchored by a large hospital and urgent care network that has steadily shifted routine testing away from central labs and a retail pharmacy sector that has kept rapid testing genuinely accessible rather than treating it as a niche offering. Strong reimbursement pathways for point-of-care testing across both public and private insurance continue supporting broad clinical adoption across the region. Ongoing hospital investment in connected device fleets that feed results directly into electronic records is further reinforcing this lead across both inpatient and outpatient care settings.

The United States accounts for the overwhelming majority of regional demand, with Canada contributing steady additional volume through its own provincial healthcare systems, which have similarly expanded near-patient testing to reduce central lab backlogs. Growing retail clinic and pharmacy-based testing continues pulling volume further from traditional hospital settings across both countries, reinforcing the region's lead even as other markets close the gap. Mexico's market remains comparatively small but is expanding as private hospital networks add near-patient testing capability to attract insured urban patients. Cross-border supply relationships tie much of North American demand together, with major manufacturers typically serving all three countries through shared distribution networks.

Asia Pacific Point of Care Diagnostics/Testing Market Insights

Asia Pacific is the fastest-growing region in the Point of Care Diagnostics/Testing Market, expanding at a CAGR of approximately 11.10% over the forecast period, with China alone expected to register the highest country-level growth rate as domestic manufacturers scale production and government healthcare access programs push testing into rural and semi-urban clinics that previously had no practical access to central lab infrastructure. Government-backed hospital modernization programs across the region continue funding new point-of-care equipment purchases well ahead of what private healthcare spending alone would support.

India's expanding private healthcare sector continues investing in rapid diagnostic capability to serve a large population outside major urban centers, while Japan and South Korea continue pushing the technology frontier with molecular and AI-assisted platforms that are gradually filtering into other regional markets as costs decline and manufacturing scale improves across the broader region. Southeast Asian markets including Vietnam and Indonesia are also beginning to scale local distribution networks, gradually narrowing the access gap with more established regional markets. Rising local manufacturing investment across the region is also gradually reducing historical reliance on imported devices from Western and Japanese suppliers.

Europe Point of Care Diagnostics/Testing Market Insights

Europe represents a substantial and technologically mature point-of-care testing market, with Germany driving regional demand through its large hospital network and strong domestic diagnostics manufacturing base. Stringent EU regulatory standards for in-vitro diagnostics have raised the bar for market entry but also reinforced clinician confidence in the devices that do reach the market, supporting steady rather than explosive regional growth relative to faster-scaling emerging markets. Ongoing consolidation among European diagnostics distributors is also improving product availability in smaller regional hospitals that previously relied on slower, centralized procurement channels. Italy and Spain contribute additional steady demand, both expanding near-patient testing within regional public hospital networks facing similar wait-time pressures.

France and the UK contribute meaningful additional volume, both expanding near-patient testing within national health systems as a way to reduce central lab wait times and emergency department bottlenecks. Growing attention to antimicrobial stewardship across the region continues reinforcing demand for rapid infectious disease testing that can distinguish bacterial from viral causes at the point of care. Nordic countries continue piloting decentralized testing programs in primary care networks, often serving as an early proving ground for technology later adopted more broadly across the wider European market.

MEA & Latin America Point of Care Diagnostics/Testing Market Insights

The Middle East and Africa represent a smaller but strategically developing point-of-care testing market, with Saudi Arabia driving regional demand through substantial healthcare infrastructure investment tied to the country's broader economic diversification goals. Growth elsewhere in the region remains closely tied to the pace of broader healthcare access expansion and government investment in rural and semi-urban clinic infrastructure. The UAE is following a similar investment path, positioning itself as a regional hub for advanced diagnostic capability serving both domestic and medical tourism demand. Egypt's growing private hospital sector is likewise adding incremental regional demand as urban healthcare access continues to expand.

Latin America is a growing market led by Brazil, where an expanding private healthcare sector and rising chronic disease prevalence continue driving demand for rapid diagnostic capability. Mexico and Argentina contribute meaningful secondary demand as their own healthcare systems gradually expand near-patient testing access across both public and private care networks. Chile and Colombia round out the region's secondary demand base, each gradually expanding near-patient testing access within both public and private hospital networks.

Market Dynamics

Growth Drivers: Chronic and infectious disease burden fueling rapid testing demand

Rising global prevalence of chronic conditions including diabetes and cardiovascular disease is one of the clearest forces behind point-of-care testing demand, since patients managing these conditions need frequent monitoring that simply isn't practical if it requires a separate lab visit every time. That everyday, recurring testing need creates a far larger and steadier demand base than acute infectious disease testing alone would generate, and it continues expanding as global chronic disease prevalence rises across both developed and emerging economies alike. Payers are also increasingly willing to reimburse frequent monitoring visits when point-of-care results demonstrably reduce downstream complications and hospitalization costs.

Continued outbreaks of infectious disease and the ongoing shift toward decentralized healthcare delivery add a second major driver, as hospitals and clinics increasingly treat rapid, near-patient results as standard practice rather than an emergency-only capability. Growing healthcare utilization in historically underserved and remote areas continues reinforcing this demand base as point-of-care devices reach settings that never had practical access to central lab infrastructure in the first place. Public health agencies in several countries have formalized point-of-care testing into standard outbreak response protocols, converting what was once emergency-only capability into permanent infrastructure.

Restraints: Accuracy trade-offs and reimbursement fragmentation limiting broader adoption

Variability in accuracy compared with central lab testing remains a genuine constraint, since clinicians and regulators alike continue to weigh a point-of-care test's speed against the small but real risk of a false result that a more controlled lab environment would have caught. That trade-off keeps some testing categories, particularly complex multi-analyte panels, tethered to central labs despite the clear convenience case for moving them closer to the patient across most other testing categories. Regulators in several markets have responded by tightening post-market surveillance requirements, adding compliance cost that smaller manufacturers find harder to absorb than established players.

Inconsistent reimbursement policy across payers and regions adds a further restraint, as point-of-care testing codes and coverage levels vary enough between insurers and countries that manufacturers and health systems face real uncertainty when building the business case for new device rollouts. Smaller clinics without dedicated billing expertise are particularly exposed to this uncertainty, occasionally delaying adoption decisions until reimbursement clarity improves. Cross-border manufacturers face a particularly complex patchwork, since a device reimbursed in one country may carry no equivalent coverage code just across the border.

Opportunities: Wearable integration and AI-assisted platforms opening new growth avenues

Integration with wearables and mobile health platforms offers manufacturers a genuine path to capturing continuous, longitudinal patient data rather than a single point-in-time reading, particularly valuable for chronic disease management where trend data matters as much as any individual result. Companies that build strong connectivity between their point-of-care devices and broader digital health ecosystems are positioned to capture disproportionate growth as this integration matures across both hospital and consumer-facing product lines. Early pilots pairing continuous glucose monitors with mobile apps have already demonstrated meaningfully better patient adherence than standalone devices, a pattern manufacturers are working to replicate across other chronic disease categories.

AI-assisted result interpretation represents a second significant opportunity, as algorithms that reduce operator-dependent reading errors make point-of-care testing viable in settings staffed by less specialized personnel. Companies that build genuine AI interpretation expertise are positioned to capture premium pricing from health systems seeking to extend rapid testing into primary care and community settings without requiring specialist-level training for every device operator. Several health systems piloting AI-assisted platforms report shorter training time for new staff, a secondary benefit that is proving almost as valuable to hospital administrators as the accuracy improvement itself.

Recent Developments:

• December 2025- Roche received FDA 510(k) clearance and a CLIA waiver for its first molecular point-of-care assay designed to identify Bordetella infections, including whooping cough, delivering results on the cobas Liat system in approximately 15 minutes.

• June 2024- F. Hoffmann-La Roche Ltd completed the acquisition of LumiraDx's U.S. point-of-care technology business, a deal aimed at strengthening the company's decentralized patient care portfolio and expanding worldwide access to rapid diagnostic results.

• June 2024- Abbott announced FDA approval for over-the-counter versions of two continuous glucose monitoring systems, Lingo and Libre Rio, extending its Libre sensor technology from a prescription-only clinical tool into a direct consumer wellness product.

• June 2024- The US FDA granted bioMérieux Special 510(k) clearance and a CLIA waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini, a compact multiplex system built for smaller clinics and urgent care settings.

• May 2024- F. Hoffmann-La Roche Ltd received FDA approval for an HPV self-testing kit designed to help detect early cervical cancer risk in women without requiring an in-clinic sample collection visit.

Point of Care Diagnostics/Testing Market Key Players

• Abbott Laboratories

• F. Hoffmann-La Roche Ltd.

• Danaher Corporation

• Siemens Healthineers AG

• Becton, Dickinson and Company (BD)

• Thermo Fisher Scientific Inc.

• Sysmex Corporation

• Bio-Rad Laboratories, Inc.

• QuidelOrtho Corporation

• bioMérieux SA

• Chembio Diagnostics, Inc.

• Trinity Biotech plc

• PTS Diagnostics

• Nova Biomedical

• OraSure Technologies, Inc.

• Sekisui Diagnostics

• Cepheid (Danaher)

• Instrumentation Laboratory (Werfen)

• Sight Diagnostics

• EKF Diagnostics Holdings plc

Point of Care Diagnostics/Testing Market Report Scope: